SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
NASDAQ:ANIK

Anika Therapeutics - ANIK Stock Forecast, Price & News

$24.62
-0.01 (-0.04%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.50
$25.01
50-Day Range
$21.74
$24.68
52-Week Range
$19.95
$45.81
Volume
46,947 shs
Average Volume
92,185 shs
Market Capitalization
$359.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
68.6% Upside
$41.50 Price Target
Short Interest
Bearish
6.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.84
Upright™ Environmental Score
News Sentiment
0.65mentions of Anika Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.45) to ($0.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

708th out of 1,075 stocks

Surgical & Medical Instruments Industry

72nd out of 104 stocks

ANIK stock logo

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Stock News Headlines

Joint Pain Injections Global Market Report 2022
Anika Therapeutics: Q2 Earnings Insights
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Company Calendar

Last Earnings
8/03/2022
Today
10/07/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
297
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$41.50
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+68.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$4.13 million
Pretax Margin
-9.83%

Debt

Sales & Book Value

Annual Sales
$147.79 million
Cash Flow
$1.42 per share
Book Value
$19.89 per share

Miscellaneous

Free Float
14,158,000
Market Cap
$359.45 million
Optionable
Optionable
Beta
0.89

Social Links


Key Executives

  • Dr. Cheryl Renee Blanchard Ph.D. (Age 58)
    Pres, CEO & Director
    Comp: $1.26M
  • Mr. Michael L. LevitzMr. Michael L. Levitz (Age 48)
    Exec. VP, CFO & Treasurer
    Comp: $683.14k
  • Mr. David Colleran (Age 50)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $649.06k
  • Ms. Anne Nunes
    VP of Operations
  • Mr. Mark Namaroff (Age 59)
    Exec. Director of Investor Relations & Corp. Communications
  • Mr. Charles Sherwood III
    VP & Corp. Legal Counsel
  • Mr. James Chase
    Sr. VP of International Sales & Marketing
  • Mr. Bart Bracy
    VP of Sales & Marketing of Americas
  • Mr. Ben Joseph
    VP of Commercial & Corp. Devel.
  • Ms. Lisa Funiciello
    VP of HR













ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price forecast for 2022?

2 analysts have issued 1 year target prices for Anika Therapeutics' shares. Their ANIK share price forecasts range from $35.00 to $48.00. On average, they expect the company's stock price to reach $41.50 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2022?

Anika Therapeutics' stock was trading at $35.83 at the beginning of 2022. Since then, ANIK stock has decreased by 31.3% and is now trading at $24.62.
View the best growth stocks for 2022 here
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ANIK earnings forecast
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its earnings results on Wednesday, August, 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.06. Anika Therapeutics had a negative trailing twelve-month return on equity of 1.96% and a negative net margin of 7.26%. During the same period in the prior year, the company posted $0.09 earnings per share.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $24.62.

How much money does Anika Therapeutics make?

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $359.45 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does Anika Therapeutics have?

The company employs 297 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.